Jade Biosciences Eyes Phase 1 Launch for JADE301 as Autoimmune Pipeline Takes Shape
Jade Biosciences has outlined plans to initiate a Phase 1 clinical trial for JADE301, its monoclonal antibody candidate targeting autoimmune diseases, with the trial expected to commence by March 2027. The milestone represents a critical de-risking event for the company's broader pipeline strategy, as the biotech looks to establish itself in the competitive but lucrative autoimmune therapeutics market. Investors in the clinical-stage space will be watching the trial initiation as a key inflectio
ViaNews Editorial Team (Finance)•